Retrospective study of the safety of caspofungin in immunocompromised pediatric patients.
Franklin
Jeremy A
JA
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, TN 381205, USA. Jeremy.Franklin@stjude.org
McCormick
John
J
Flynn
Patricia M
PM
D000293:Adolescent; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D054714:Echinocandins; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D055666:Lipopeptides; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology*; D010455:Peptides; D010456:Peptides, Cyclic; D012189:Retrospective Studies; D018570:Risk Assessment; D012494:Sampling Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin